Multiple platelet defects identified by flow cytometry at diagnosis in acute myeloid leukaemia

British Journal of Haematology
Eva Birgitte LeinoeH E Johnsen

Abstract

Summary Previous findings of megakaryocytic hypogranulation and dysmegakaryocytopoietic features in acute myeloid leukaemia (AML) strongly indicate defects in platelet production. The bleeding tendency of these patients may result from dysregulated platelet production, resulting in thrombocytopenia as well as qualitative platelet defects. The present study examined platelet function at diagnosis in 50 AML patients by whole blood flow cytometry. Following in vitro platelet agonist stimulation, platelet activation markers were analysed and compared with 20 healthy individuals. To detect recent in vivo platelet activation, plasma soluble P-selectin (sP-selectin) was measured. Flow cytometric analysis of platelet activation markers demonstrated reduced CD62P [35.6 vs. 118.5 x 10(3) molecules of equivalent soluble fluorochrome (MESF); P < 0.0001], CD63 (11.3 vs. 50.7 x 10(3) MESF; P < 0.0001), and PAC-1 (41.5 vs. 90.5%; P = 0.0001) while reductions in CD42b were abnormal (45.6 vs. 70%; P < 0.0001). sP-selectin levels were similar in patients and healthy controls (0.04 vs. 0.27 fg/platelet; P = 0.84). The presented data indicate that AML pathogenesis may result in multiple platelet defects, involving adhesion, aggregation, and secret...Continue Reading

References

Aug 1, 1978·British Journal of Haematology·P GangulyH R Bradford
Jan 1, 1992·Seminars in Thrombosis and Hemostasis·A D Michelson
Apr 1, 1992·The Journal of Experimental Medicine·L C DunlopM C Berndt
Jul 1, 1987·British Journal of Haematology·A GuariniS Tura
Nov 15, 1985·Analytical Biochemistry·L A FitzgeraldD R Phillips
Oct 1, 1974·British Journal of Haematology·W QueisserH Heimpel
Nov 1, 1972·Australian and New Zealand Journal of Medicine·M B Van der WeydenB G Firkin
Dec 1, 1984·Journal of Clinical Pathology·B E WoodcockF E Preston
Jun 17, 1998·The Journal of Laboratory and Clinical Medicine·A C MatzdorffH Pralle
Mar 4, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·N L HarrisC D Bloomfield
Feb 4, 2003·Nature Reviews. Cancer·Daniel G Tenen
Aug 13, 2003·Current Opinion in Hematology·Pamela B Conley, Suzanne M Delaney
Feb 1, 1964·Archives of Internal Medicine·I A FRIEDMANS L LEITHOLD
Jan 23, 2004·Leukemia·D Grimwade, T Enver

❮ Previous
Next ❯

Citations

Feb 3, 2005·British Journal of Haematology·Eva Birgitte LeinoeHans Erik Johnsen
Mar 16, 2017·Journal of Thrombosis and Haemostasis : JTH·P J VinholtC Nielsen
Sep 9, 2006·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Jyothi MaddineniJawed Fareed
Aug 30, 2019·Clinical Chemistry and Laboratory Medicine : CCLM·Pernille J Vinholt
May 24, 2019·American Journal of Hematology·Pernille Just VinholtChristian Nielsen
Sep 17, 2021·British Journal of Haematology·Cecilia KarlströmPetter Höglund
Sep 4, 2021·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Nanna BrønsSisse R Ostrowski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.